Overview

Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma

Status:
RECRUITING

Trial end date:
2033-02-20

Target enrollment:

Participant gender:

Summary

This is a single- arm, open-label, multicenter, phase II study to evaluate Acalabrutinib plus Rituximab for the treatment of elderly or low- to intermediate-risk younger untreated mantle cell lymphoma

Phase:

PHASE2

Details

Lead Sponsor:

Sun Yat-sen University

Treatments:

acalabrutinib
Rituximab